DoW Breast Cancer, Clinical Research Extension Award
Funds breast cancer clinical research extensions that continue data collection, follow-up, and analysis of existing clinical studies for eligible applicants, with consumer advocate participation required.
⚑ Breast Cancer Research Program award mechanism; all applications must address at least one FY26 BCRP overarching challenge or justify an exception. · Research team must include two or more breast cancer consumer advocates. · Partnering PI option requires a pre-application from the Initiating PI and full applications from both PIs; missing any required submission may cause administrative withdrawal.
Unit fits — one characterization, each unit's own rules
| IPPRA | 58 good | portfolio topic: public_health; social/behavioral work is minor; funds evaluation research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped) |
| Physical Sciences & Engineering (demo) | 40 partial | technical depth: substantial; funds evaluation research (capped) |
| Tom Love Innovation Hub | 15 none | deep-tech content; no commercialization signal |
Description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception .
Distinctive Features:
· The research team must include two or more breast cancer consumer advocates.
· This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Apply
View on Grants.gov → CONTACT: Jamie Shortall Grant Officer <help@eBRAP.org>
Proposal brief
Proposal shell · Department of Defense (BAA-style) conventions
Legacy IPPRA LLM assessment (v2.0, for comparison)
0/100 · gpt-5.4-mini · 2026-07-06
This is a biomedical clinical research extension award focused on breast cancer patient data collection, follow-up, and analysis. It has some public-health relevance, but the mechanism is centered on clinical oncology research rather than IPPRA’s core strengths in behavioral, policy, risk-communication, or population-level social science. Public universities appear eligible, but the opportunity is still a poor fit for IPPRA because it is not aimed at the institute’s signature human-side-of-technical-systems research.
Legacy scoring history
| 2026-07-06 | 0 | gpt-5.4-mini | This is a biomedical clinical research extension award focused on breast cancer patient data collection, follow-up, and analysis. It has some public-health relevance, but the mechanism is centered on clinical oncology research rather than IPPRA’s core strengths in behavioral, policy, risk-communication, or population-level social science. Public universities appear eligible, but the opportunity is still a poor fit for IPPRA because it is not aimed at the institute’s signature human-side-of-technical-systems research. |
| 2026-07-06 | 0 | gpt-5.4-mini | This is a breast cancer clinical research extension award, so the core topic is biomedical rather than IPPRA’s main social-science and policy domains. The required inclusion of consumer advocates suggests some patient/community engagement, but the opportunity is still centered on clinical data collection and analysis rather than communication, behavior, or policy research. Public universities appear eligible as research performers, so this is not ineligible on applicant grounds. |